

Re: Freedom of Information Request

Thank you for your request for information made under the Freedom of Information Act 2000 which was received into this office on 31st August 2017.

You Asked for information regarding gain share agreements:
1. Are there any gainshare agreements in place between you the CCG and a provider (e.g. hospital trust)?

Please note NHS Wirral CCG have given Indication opposed to Disease Area as this detail is not available.

Agreement	Indication	Provider included in the gainshare agreement	Name of specific drugs involved	Savings apportioned between CCG and the provider
1. Home Care Drugs	Ankylosing Spondylitis	Wirral University Teaching Hospital	Adalimumab	£ 7,183.66
			Certolizumab	£ 858.00
			Etanercept	£ 3,552.24
	Chronic psoriasis	Wirral University Teaching Hospital	Adalimumab	£ 493.00
			Etanercept	£ 152.00
	Crohns	Wirral University Teaching Hospital	Adalimumab	£ 352.14
	Crohn's disease	Wirral University Teaching Hospital	Adalimumab	£ 41,763.80
	Growth hormone deficiency	Wirral University Teaching Hospital	Somatropin	£ 356.37
	Haematological Anaemia	Wirral University Teaching Hospital	Darbepoetin	£ 1,827.81
	Idiopathic thrombocytopenic purpura	Wirral University Teaching Hospital	Romiplostim	£ 3,470.40
			Romiplostim Delivery	£ 27.50
	Immune Thrombocytopenic purpura	Wirral University Teaching Hospital	Romiplostim Delivery	£ 5.50
	Juvenile Idiopathic Arthritis	Wirral University Teaching Hospital	Adalimumab	£ 1,126.85
			Etanercept	£ 429.00
	Non-Radiographic Axial Spondyloarthritis	Wirral University Teaching Hospital	Adalimumab	£ 140.86
	Osteoporosis	Wirral University Teaching Hospital	Teriparatide	£ 190.32
	Psoriasis	Wirral University Teaching Hospital	Adalimumab	£ 15,071.59
			Apremilast	£ 299.25
			Etanercept	£ 1,584.25
			SECUKINUMAB	£ 1,442.34
			Ustekinumab	£ 12,023.20
	Psoriatic Arthritis	Wirral University Teaching Hospital	Adalimumab	£ 8,873.93
			Certolizumab	£ 786.50
			Etanercept	£ 1,950.00
			Golimumab	£ 1,188.18
	Rheumatoid arthritis	Wirral University Teaching Hospital	Ustekinumab	£ 429.40
			Abatacept	£ 8,805.68
			Adalimumab	£ 20,917.12
			Certolizumab	£ 12,012.00
			Etanercept	£ 14,142.48
Seronegative Arthritis	Wirral University Teaching Hospital	Golimumab	£ 5,027.76	
		Tocilizumab	£ 6,451.20	
		Certolizumab	£ 429.00	
Ulcerative Colitis	Wirral University Teaching Hospital	Etanercept	£ 76.00	
		Adalimumab	£ 1,267.70	
			Golimumab	£ 6,150.78

2. Do you have any other agreements with a provider to switch from branded to biosimilar products?

NHS Wirral CCG currently does not have a formal agreement in place with our main acute provider WUTH for biosimilars but they are switching from brands to biosimilars and have a Biosimilar Steering Group set up for 17/18

3. Are there any other agreements between you the CCG and a provider, not included in the above, for the following services?

No other arrangements.

We hope this information is useful, however if you require any further information please do not hesitate to contact a member of the Corporate Affairs Team (contact details at the top of this letter)

Re- Use of Information

Most of the information that we provide in response to Freedom of Information Act 2000 requests will be subject to copyright protection. In most cases the copyright will be owned by Wirral Clinical Commissioning Group. The copyright in other information may be owned by another person or organisation, as indicated on the information itself.

You are free to use any information supplied for your own non-commercial research or private study purposes. The information may also be used for any other purpose allowed by a limitation or exception in copyright law, such as news reporting. However, any other type of re-use, for example by publishing the information in analogue or digital form, including on the internet, will require the permission of the copyright owner.

For information where the copyright is owned by Wirral Clinical Commissioning Group please e-mail foirequests.nhsuiralccg@nhs.net to request a reuse licence.

For information where the copyright is owned by another person or organisation you must apply to the copyright owner to obtain their permission.